| __timestamp | Apellis Pharmaceuticals, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 3852327 |
| Thursday, January 1, 2015 | 6356782 | 839656 |
| Friday, January 1, 2016 | 4303743 | 4478145 |
| Sunday, January 1, 2017 | 10463151 | 16432324 |
| Monday, January 1, 2018 | 22639184 | 11890871 |
| Tuesday, January 1, 2019 | 67046483 | 34110000 |
| Wednesday, January 1, 2020 | 139401000 | 35781000 |
| Friday, January 1, 2021 | 176771000 | 40896000 |
| Saturday, January 1, 2022 | 277163000 | 52200000 |
| Sunday, January 1, 2023 | 500815000 | 59836000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing expenses is crucial for success. Apellis Pharmaceuticals, Inc. and Merus N.V. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Apellis Pharmaceuticals has seen a staggering increase of over 17,000% in SG&A expenses, peaking at approximately $500 million in 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Merus N.V. has maintained a more conservative growth, with SG&A expenses increasing by around 1,500% over the same period, reaching nearly $60 million in 2023. This difference highlights the varied strategic approaches of these companies in navigating the biotech landscape. As investors and industry watchers, understanding these financial dynamics can provide valuable insights into each company's operational priorities and market positioning.
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Novartis AG vs Merus N.V.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Merus N.V.
Selling, General, and Administrative Costs: Verona Pharma plc vs Merus N.V.
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Mesoblast Limited
Apellis Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Merus N.V. and Mesoblast Limited